€125.86
Your prediction
Agilent Technologies Inc. Stock
Agilent Technologies is a leading global manufacturer of measuring instruments, software, services, and solutions for chemical analysis, life sciences, diagnostics, and electronic testing. The company provides a broad range of products from laboratory equipment to genetic testing tools and clinical diagnostics. Agilent's instruments are widely used in research laboratories, pharmaceutical companies, and government agencies, making it a significant player in the life sciences industry. The company operates in more than 100 countries and has a history of innovation, having developed some of the world's first portable gas chromatographs and UV-Vis spectrophotometers. Agilent's stock is traded on the New York Stock Exchange under the symbol "A."
Pros and Cons of Agilent Technologies Inc. in the next few years
Pros
Cons
Performance of Agilent Technologies Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Agilent Technologies Inc. | 0.100% | -0.929% | 4.500% | 14.783% | -0.269% | -13.050% | 101.473% |
Waters Corp. | -0.260% | -1.481% | 10.310% | 22.400% | 1.325% | -11.047% | 61.443% |
QuidelOrtho Corp. | -1.480% | 0.000% | 15.205% | -47.634% | -41.905% | -61.542% | -24.780% |
Illumina Inc. | 0.810% | -0.710% | 10.272% | -22.194% | -8.607% | -71.159% | -53.230% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial review, the financials of Agilent Technologies (US Symbol: A) from the Healthcare Equipment & Supplies industry appear to show steady growth and financial stability. The company has managed to increase its net income and total assets over the past few years, suggesting a strong and expanding financial position. This combined with a generally positive industry trend makes Agilent Technologies an interesting player in the healthcare equipment and supplies sector.
Pros
Revenue Growth: From 2020 to 2022, Agilent's total revenue increased from $5.34 billion to $6.85 billion, demonstrating consistent growth. This steady uptick in revenues suggests promising business prospects and an expanding market share in the industry.
Comments
News
![Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5oVVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b69713a1a725bfbdb6127b83617e316a5f0244d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-claim_flatex-at_positiv_rgb.png?locale=us)
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of
![Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOE9jVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35d3dc71bc91537c00371e80355e9bfbbf3e14d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/sw_wf.png?locale=us)
Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance
Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column
![Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWZ1S2c9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--645dcd16b794e331d9eb102d9e92e0f824b8175e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/plane-841441_1280.jpg?locale=us)
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy
Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with